Quantum Leap Healthcare Collaborative

Partner with Us

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.

The Efficient and Innovative design of I-SPY 2 offers all of our partners — clinical researchers, patient advocates, pharmaceutical and diagnostics companies, and non-profit charities — the opportunity to participate in and contribute to acceleration of drug development to treat breast cancer patients in the neoadjuvant setting.

The I-SPY Trials are always looking to discuss potential partnerships with companies interested in evaluating promising new agents or analytical methods.

To learn more about partnerships with I-SPY, please contact Paul Henderson at p.henderson@quantumleaphealth.org

Stay tuned for more information on I-SPY partnership opportunities.